The state of North Carolina currently has 18 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Durham, Charlotte, Winston-Salem and Chapel Hill.
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Recruiting
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: TG Therapeutics Investigational Trial Site, Charlotte, North Carolina +1 locations
Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Recruiting
The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: PROVIDE Virtual Research Coordination Center, Wilmington, North Carolina
Conditions: Relapsing Multiple Sclerosis
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
Recruiting
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study. In Part 1, one set of participants will take either BIIB091 or diroximel fumarate (DRF). In Part 2, a different set of participants will take either a combination of BIIB091 and DRF or DRF alone. The goal of the study is to learn more about the safety of BIIB091 and to compare the effects of the study drug when taken alone or together with... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/20/2025
Locations: Wake Forest University - School of Medicine - Central, Winston-Salem, North Carolina
Conditions: Relapsing Forms of Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: The Neurological Institute PA, Charlotte, North Carolina +1 locations
Conditions: Relapsing Multiple Sclerosis
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Recruiting
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/07/2025
Locations: ZEPOSIA MS Pregnancy Registry, Wilmington, North Carolina +1 locations
Conditions: Multiple Sclerosis
Retinal Imaging in Neurodegenerative Disease
Recruiting
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Mild Cognitive Impairment, Multiple Sclerosis, Huntington Disease, Neuro-Degenerative Disease, Alzheimer's Disease, Parkinson's Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Normal Cognition